<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264043</url>
  </required_header>
  <id_info>
    <org_study_id>EC99-09</org_study_id>
    <nct_id>NCT00264043</nct_id>
  </id_info>
  <brief_title>The Study to Evaluate Patient Outcome Using Distal Protection Combined With the BX Velocity.</brief_title>
  <acronym>DISCOVER</acronym>
  <official_title>Distal Protection Combined With Velocity in Coronary Arteries and SVBG Registry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the use of the AngioGuard™ device combined with the Bx
      Velocity™ on patient outcome at one month.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, multi-center trial. Patients will be treated with the
      AngioGuard™ device and Bx Velocity™ stent and will be followed for six-months post-procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">February 2002</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical success of the AngioGuard™ device combined with the Bx Velocity™ stent</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>successful placement and retrieval without embolic occlusions of vessels distal to the position of the device</measure>
    <time_frame>post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rates</measure>
    <time_frame>1 month and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>device evaluation</measure>
    <time_frame>post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AngioGuard™ device and Bx Velocity™ stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>emboli capturing guidewire device combined with stent</intervention_name>
    <description>AngioGuard™ device and Bx Velocity™ stent</description>
    <arm_group_label>1</arm_group_label>
    <other_name>emboli capturing guidewire device</other_name>
    <other_name>PTCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unstable angina pectoris (Braunwald classification B &amp; C, I-II-III, native vessels)

          -  or lesion located in the SVG;

          -  Single de novo or restenotic lesion requiring treatment in a major native coronary
             artery or saphenous vein graft;

          -  The vessel diameter to place the AngioGuard™ device in must be &gt; 3 and &lt; 5.5 mm (6.5
             when the 7mm AngioGuard™ is available);

          -  Target lesion stenosis is &gt;50% and &lt;100% (TIMI 1).

        Exclusion Criteria:

          -  A Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the
             CK and CK-MB enzymes are back to normal;

          -  More than one coronary artery is 100% occluded;

          -  Patient has unprotected left main coronary disease with &gt; 50% stenosis;

          -  Patient has an ostial target lesion;

          -  Significant (&gt;50%) untreated stenosis proximal or distal to the target lesion that
             will be treated during the procedure, since this may require revascularization or
             impede runoff;

          -  Ejection fraction &lt;30%;

          -  Totally occluded vessel (TIMI 0 Level).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eberhard Grube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Siegburg GMBH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Siegburg GMBH</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2005</study_first_posted>
  <last_update_submitted>August 5, 2008</last_update_submitted>
  <last_update_submitted_qc>August 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

